From the Journals

Genes may play role in breast cancer racial disparities


 

FROM JAMA ONCOLOGY

A new analysis of data from The Cancer Genome Atlas revealed 142 genes differentially expressed between white and African Americans that may influence breast cancer survival.

African American patients were more likely than were whites to have basal-like breast cancer (odds ratio [OR], 3.80; 95% confidence interval [CI], 2.46-5.87; P less than .001) and HER2-enriched breast cancer (OR, 2.22; 95% CI, 1.10-4.47; P =.027).

After adjustment for subtype, 142 genes were differentially expressed between the two populations, a finding that held true after correction for testing of multiple comparisons (Bonferroni-adjusted P less than .05), reported Dezheng Huo, MD, PhD, of the department of public health sciences, University of Chicago, and his coauthors (JAMA Oncol. 2017 May 4. doi: 10.1001/jamaoncol.2017.0595).

During a median follow-up of 29 months, African Americans were more likely to experience recurrences (hazard ratio [HR], HR = 1.67, 95 CI, 1.02-2.74; P =.043). They had higher odds of basal-like breast cancer (OR, 3.80; 95% CI, 2.46-5.87; P less than .001) and human epidermal growth factor receptor 2 ERBB2 (HER2)-enriched breast cancer (OR, 2.22; 95% CI, 1.10-4.47; P =.027).

After adjusting for intrinsic subtypes, the researchers found differential expression of 16 DNA methylation probes, 4 DNA copy number segments, and 1 protein,

Dr. Olufunmilayo I. Olopade of the University of Chicago

Dr. Olufunmilayo I. Olopade

“It gives us a road map to begin to dig deeper into solving a lot of the challenges we had had in terms of describing disparities, and what we need to do to move forward,” coauthor Olufunmilayo I. Olopade, MD, professor of medicine and human genetics and director of the center for clinical cancer genetics at the University of Chicago, said in a press statement.

“If you have African ancestry, you’re more likely to have tumors that grow really fast. If we have drugs that can treat that kind of tumor, we need to find you and get you into treatment as quickly as possible,” she said.

Recommended Reading

Only some genes count in breast cancer panels
MDedge ObGyn
Palbociclib/fulvestrant works in Asians with HR+/HER2– breast cancer too
MDedge ObGyn
Risk of recurrence outweighs risk of contralateral breast cancer for DCIS patients
MDedge ObGyn
Study underscores aggressive approach to inflammatory breast cancer
MDedge ObGyn
Lumpectomy plus reconstruction outperforms mastectomy plus reconstruction
MDedge ObGyn
Sutureless, guided lumpectomy produced clean margins in majority
MDedge ObGyn
Mastectomy unnecessary for some breast cancer recurrences
MDedge ObGyn
Breast density is no reason to perform MRI
MDedge ObGyn
Two new biomarkers show breast cancer validity
MDedge ObGyn
Androgen receptor screening not ready for triple-negative breast cancer
MDedge ObGyn